1. An association of low-density lipoproteins and fibrinolysis in patients with severe aortic stenosis- valvular expression of fibrinolytic proteins. (14th October 2021) Authors: Kopytek, M; Undas, A; Natorska, J Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Antiphosphatidylserine/prothrombin (aPS/PT) antibodies are associated with Raynaud phenomenon and migraine in primary thrombotic antiphospholipid syndrome. (April 2018) Authors: Kopytek, M; Natorska, J; Undas, A Journal: Lupus Issue: Volume 27:Number 5(2018) Page Start: 812 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Non-vitamin K antagonist oral anticoagulants (NOACs) attenuate valvular calcification in patients with severe aortic stenosis. (3rd October 2022) Authors: Kopytek, M; Tarasiuk, J; Wronski, S; Undas, A; Natorska, J Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Rivaroxaban attenuates valvular inflammation and tissue remodeling in patients with severe aortic stenosis. (14th October 2021) Authors: Kopytek, M; Zabczyk, M; Undas, A; Natorska, J Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗